Temanogrel

DRUG2 trials

Sponsors

Pfizer

Conditions

Microvascular ObstructionRaynaud's Phenomenon Secondary to Systemic Sclerosis

Phase 2

A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention

TerminatedNCT04848220

PfizerMicrovascular Obstruction

Start: 2021-05-20End: 2022-08-31Updated: 2023-12-12

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis

TerminatedNCT04915950

PfizerRaynaud's Phenomenon Secondary to Systemic Sclerosis

Start: 2021-11-03End: 2022-09-02Updated: 2023-12-22